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Abstract
Pulmonary artery aneurysms (PAA) can be complicated with pulmonary arterial hypertension (PAH), causing sudden death due to
PA rupture and dissection. Because treatment with PAH-targeted drugs does not always prevent PAA progression, prophylactic
surgical repair of the PAA seems a promising alternative. However, although it avoids rupture and dissection of the PAs, additional
benefits have not been forthcoming. We therefore present two patients with co-existing PAH and a PAA who underwent surgical
repair of the aneurysm. Following the surgery, their lung function and pulmonary hypertension improved. Optimal treatment of
PAA remains uncertain, however, with no clear guidelines regarding the best therapeutic approach. This case series provides
physicians with reasons to repair PAA surgically in patients with PAH.
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Introduction
Pulmonary artery aneurysms (PAA) are sometimes asso-
ciated with pulmonary arterial hypertension (PAH).1
A PAA can be an independent risk factor for unexpected
death due to aneurysm rupture or dissection in patients with
PAH.2 Because it is known that PAAs progress in patients
with PAH despite treatment for the pulmonary hypertension
(PH),3 prophylactic surgical repair of a PAA could be a
treatment option.4 The benefit of surgical repair of a PAA
is that it precludes the possibility of its rupture and dissec-
tion. Any additional benefits of such surgical repair of a
PAA in the presence of PAH have not been elucidated.
We therefore present two patients, each with coexisting
PAH and a PAA, who underwent surgical repair of the
aneurysm and whose lung function and PH improved.
Case report 1
A 63-year-old woman had been diagnosed with idiopathic
PAH at the age of 49 years. At that time, contrast-
enhanced computed tomography (CT) showed a large
PAA (diameter 67mm). Right heart catheterization (RHC)
showed a mean pulmonary artery pressure (mPAP) of
75mmHg. She was started on beraprost with sequentially
added bosentan at the age 51 years and sildenafil at 54 years.
The bosentan was changed to ambrisentan at age 57 years
and the sildenafil to riociguat at the age of 60 years.
Although mPAP decreased to 44mmHg, the PAA’s diam-
eter had expanded to 129mm (Fig. 1a), and her SpO2 was
95% with oxygen administration at 4L/min. She had exer-
tional breathlessness and was in World Health Organization
(WHO) functional class (FC) II. We therefore decided to
repair the PAA surgically. When she was aged 61 years,
we reconstructed the right ventricular outflow tract and per-
formed bilateral pulmonary artery plication (Fig. 1b). Seven
months postoperatively, RHC showed a mPAP of 35mmHg
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(with the patient on ambrisentan and riociguat). Lung
perfusion scintigraphy showed that a preoperative perfusion
ratio in her left upper and middle lung had increased post-
operatively (Fig. 1c and d). In addition, the lung function
test showed that her preoperative vital capacity of 1.7L
(71.4% of predicted value) had increased postoperatively
to 2.4 L (93.7% of predicted value). Her SpO2 was 99%
with oxygen administration at 1L/min. Precise clinical,
echocardiographic, and hemodynamic parameters, lung
function test, and blood gas test of case 1 before and after
surgery of PAA are shown in Table 1.
Case report 2
A 61-year-old woman had been diagnosed at the age of
31 years with portopulmonary hypertension associated
with a congenital portosystemic venous shunt. At age
50 years, CT demonstrated a large PAA (diameter 71mm).
RHC showed a mPAP of 52mmHg. Bosentan was initiated;
tadalafil was added sequentially at age 54 years. Bosentan
was changed to ambrisentan at age 56 years. Although her
mPAP had decreased to 41mmHg, the aneurysm’s diameter
had expanded to 133mm (Fig. 1e), and her SpO2 was 95%
with oxygen administration at 3L/min. She underwent coil
occlusion of a congenital portosystemic venous shunt and
intravenous epoprostenol was added to the regimen. She
had exertional breathlessness, cough, and general fatigue
and was in WHO FC III. Because the mPAP had decreased
to 35mmHg, we decided repair the aneurysm surgically.
At the age of 61 years, she underwent reconstruction of
the right ventricular outflow tract and bilateral pulmonary
artery plication (Fig. 1f). RHC performed nine months post-
operatively showed a mPAP of 26mmHg (with the patient
on ambrisentan, tadarafil, and selexipag). Lung perfusion
scintigraphy showed that a preoperative perfusion ratio in
her left upper and middle lung had increased postoperatively
(Fig. 1g and h). The lung function test revealed that her
preoperative vital capacity of 1.6L (57.8% of predicted
value) increased postoperatively to 2.2 L (82.3% of pre-
dicted value). Also, her SpO2 was 99% with oxygen admin-
istration at 2L/min. Precise clinical, echocardiographic, and
hemodynamic parameters, lung function test, and blood gas
test of case 2 before and after PAA surgery are shown in
Table 1.
Discussion
PAA is defined as the main pulmonary artery diameter
measuring> 40mm.5 Its prevalence was approximately 1
in 14,000 autopsies.6 Elevated PAP, high flow, connective
tissue diseases, pulmonary valve stenosis, systematic vascu-
litis, infections, and trauma are the most probable causes
of a PAA.1 Dissection or rupture of PAA is rare but life-
threatening. Hence, prophylactic treatment for PAA is
required—although there is no clear evidence that one or
another treatment/therapeutic strategy for PAA is more
effective than any other. Reduced hemodynamic stress on
the pulmonary artery wall might help prevent the formation
and progression of PAA because increased shear stress
would injure a pulmonary artery wall.7 However, lowering
the PAP by PAH-targeted drugs has not always prevented
PAA progression.3,8 Aggressive surgical intervention has
also been advocated for patients with PAH.
To date, although surgical repair of PAA precludes the
possibility of impending dissection and rupture, there has
been no evidence reported that the repair offers additional
benefits. In our two patients, however, their vital capacity
increased after repairing the PAA. We think that expansion
of the left upper and middle lung, which had been com-
pressed by the PAA in each patient, resulted in the improved
lung function. In addition, repair of the PAA recanalized the
left upper and middle pulmonary artery, which allowed
increased pulmonary blood flow. Thus, these ventilation
and perfusion recoveries in the left upper and middle lung
could lead to improved oxygenation. Furthermore, expan-
sion of the pulmonary vascular bed could result in reduced
Fig. 1 Chest CTand lung perfusion scintigraphy. Top: Before repair of a PAA. Bottom: After repair of a PAA. (a, b) Contrast-enhanced CTof case
1. (c, d) Lung perfusion scintigraphy of case 1. (e, f) Contrast-enhanced CT of case 2. (g, h) Lung perfusion scintigraphy of case 2. CT, computed
tomography; PAA, pulmonary artery aneurysm.
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hemodynamic stress, thereby contributing to decreased
PAP. Hence, we believe that there are additional benefits
of surgical repair of PAA. They are improved lung function
and PH in patients with PAH.
Kreibich et al. recommended the following indications
for PAA surgery: (1) an absolute PAA diameter of
5.5 cm; (2) increase in the aneurysm’s diameter of
0.5 cm within six months; (3) compression of adjacent
structures; (4) thrombus formation in the aneurysm sac;
(5) appearance of clinical symptom; (6) evidence of valvular
pathology or a shunt; (7) verification of PAH; (8) signs of
rupture or dissection.1 More evidence is needed to know
whether the benefit of therapeutic intervention exceeds the
risk of the surgery. We think that appropriate indications
for PAA surgery would provide the benefit of therapeutic
intervention beyond risks of the surgery. Preoperative lung
function test showed the reduced vital capacity and mixed
pattern in both cases. Preoperative lung perfusion scintig-
raphy showed the reduced perfusion ratio in lung com-
pressed by PAA in both cases. Cardiac output (CO) was
also an important factor for indication for PAA surgery.
There were some case reports and series of PAA surgery
with or without PAH. In reports with patients without
PAH who were received PAA surgery, CO was not
described,9,10 but ejection fraction was preserved
(EF¼ 51%).10 In reports of patients with PAH who received
PAA surgery, CO was not described.11 In a report of
a patient with PAH who did not receive PAA surgery, the
patient had a low cardiac index (2.5 L/min/m2) and died
although the patient was treated with PAH-specific
drugs.12 Decreased CO was an independent risk factor of
all all-cause mortality in PAH patients with PAA.2 In our
cases, CO was relatively preserved before PAA surgery.
In our opinion, these respiratory function, image findings,
and preserved CO would be factors of indication for PAA
surgery.
The diameter of PAA at diagnosis was> 55mm in both
cases. However, we chose not to operate on the patients then
because PAP was high (Case 1: mPAP¼ 75mmHg, Case 2:
mPAP¼ 52mmHg) and PH was not stable in both cases.
Thereafter, we chose to operate patients because mPAP
decreased, PH improved, and CO was relatively preserved,
but hypoxia progressed.
As these two cases suggested, surgical repair of a PAA
could achieve improved lung function and PH. Therefore,
we believe that the presence of reduced vital capacity,
reduced perfusion ratio in lung compressed by PAA, and
severe oxygen desaturation indicate the need to consider
surgical repair of a PAA.
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Table 1. Clinical, echocardiographic, and hemodynamic parameters,
lung function test, and blood gas test of patients before and after
surgery of PAA.
Case 1 Case 2
Parameters Pre Post Pre Post
Clinical
WHO FC II II III II
Echocardiographic
TR Trivial Trivial Mild Mild
TRPG (mmHg) 68 49 55 44
TAPSE (mm) 13 13 12 14
S’ (cm/s) 9 9 8 8
RVFAC (%) 35 33 32 29
Hemodynamic
PAP (s/d/m) (mmHg) 62/35/44 63/16/35 56/17/35 50/14/26
RVSP/EDP (mmHg) 62/2 75/0 57/8 54/6
RAP (mmHg) 2 0 8 6
PAWP (mmHg) – 0 – 14
CO (L/min) 2.3 3.6 5.7 8.1
CI (L/min/m2) 1.6 2.5 3.9 5.3
PVR or TPR
(Wood units)
19* 10 6* 2
Lung function test
VC (L) 1.7 2.4 1.6 2.2
%VC (%) 71.4 93.7 57.8 82.3
FEV1.0 (L) 1.03 1.59 0.95 1.24
FEV1.0% (%) 66.0 69.4 60.0 58.2




4 L – 4 L 2 L
pH 7.4 – 7.4 7.4
PaO2 (mmHg) 94.7 – 72.2 88.3
PaCO2 (mmHg) 33.9 – 45.9 43.4
*Values are TPR because PAWP was not measured due to large PAA.
WHO FC, World Health Organization functional class; TR, tricuspid regurgi-
tation; TRPG, tricuspid regurgitation pressure gradient; TAPSE, tricuspid annu-
lar plane systolic excursion; S’, tricuspid annular velocity; RVFAC, right
ventricular fractional area change; PAP, pulmonary artery pressure; s/d/m, sys-
tolic/diastolic/mean; RVSP, right ventricular systolic pressure; RVEDP, right ven-
tricular end diastolic pressure; RAP, right atrial pressure; PAWP, pulmonary
artery wedge pressure; CO, cardiac output; CI, cardiac index; PVR, pulmonary
vascular resistance; TPR, total pulmonary resistance; VC, vital capacity; FEV1.0,
forced expiratory volume in 1 s.
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